Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
ABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy Manufacturing
Tuesday, April 08, 2025ABEC a global leader in engineering solutions and services for biotechnology manufacturing has launched its Advanced Therapy Bioreactor ATB This revolutionary platform has the potential to change the way cells for advanced therapy
Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company
Monday, April 07, 2025Epsilogen the global leader in the development of immunoglobulin E IgE antibody therapeutics today announces that it has completed the acquisition of TigaTx Inc a biotechnology company developing engineered immunoglobulin A IgA antibodies to create t...
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
Friday, April 04, 2025NBE Therapeutics NBE a wholly owned subsidiary of Boehringer Ingelheim officially opened its new ADC RD facility in Basel This milestone reinforces its commitment to innovation in oncology and strengthens its footprint in Switzerlands biotech ecosys...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Friday, April 04, 2025The US Food and Drug Administration FDA has granted orphan drug designation to rilzabrutinib an investigational novel advanced oral reversible Brutons tyrosine kinase BTK inhibitor for two rare diseases warm autoimmune hemolytic anemia wAIHA and IgGr...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Thursday, April 03, 2025Novartis today announced the US Food and Drug Administration FDA has granted accelerated approval for Vanrafia atrasentan a potent and selective endothelin A ETA receptor antagonist for the reduction of proteinuria in adults with primary immunoglobul...
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
Thursday, April 03, 2025Averoa a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases today announces a positive opinion from the European Medicines Agency EMAs Committee for Medicinal Products for Human Use CHMP for XOANACYL an...
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma
Tuesday, April 01, 2025AstraZenecas Calquencein combination with bendamustine and rituximab has been recommended for approval in the European Union EU for the treatment of adult patients with previously untreated mantle cell lymphoma MCL who are not eligible for autologous...
Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention
Tuesday, April 01, 2025H Lundbeck AS Lundbeck is announcing reaching recruitment target in the SC dosefinding part Part A in the phase IIb PROCEED trial that explores dose and route of administration of the antiPACAP mAb Lu AG
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Saturday, March 29, 2025Novartis announced today that the US Food and Drug Administration FDA approved Pluvicto lutetium Lu vipivotide tetraxetan for patients with prostatespecific membrane antigen PSMApositive metastatic castrationresistant prostate cancer
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Friday, March 28, 2025LIXTE Biotechnology Holdings Inc a clinicalstage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy today provided an update on its recent activities
